Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report

BACKGROUND: Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its intravenous formulation, has been used since 2006 for the treatment of CMML, us...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheel, Ankur, Bae, Junu, Asada, Ashlee, Otterson, Gregory A., Baliga, Ragavendra R., Koenig, Kristin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845814/
https://www.ncbi.nlm.nih.gov/pubmed/36653885
http://dx.doi.org/10.1186/s40959-023-00153-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845814/
https://www.ncbi.nlm.nih.gov/pubmed/36653885
http://dx.doi.org/10.1186/s40959-023-00153-6

Ejemplares similares